BioSpace News Archive

Mablink Bioscience (“Mablink”) today announced that preclinical efficacy and safety data on its lead ADC candidate, MBK-103, will be presented at the American Association for Cancer Research (“AACR“) Meeting 2023 on April 17, 2023, in Orlando, Florida.

Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced an upcoming preclinical data poster presentation supporting the ongoing clinical development of its ALK-selective inhibitor, NVL-655.

Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”) today announced that a clinical trial abstract for its investigational pan-RAF inhibitor exarafenib has been selected for an oral presentation during the Clinical Trials Mini Symposium Session at the American Association for Cancer Research (AACR) 2023 Annual Meeting, being held April 14-19 in Orlando, Fla.

Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immuno-oncology company developing novel T cell engagers, today announced that it will present data from five preclinical investigations in poster presentations at the American Association for Cancer Research (AACR) Annual Meeting being held in Orlando, Fla., April 14-19, 2023.

Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX) today announced that new data will be presented demonstrating the promise of its SORT1+ Technology™ platform of proprietary peptides, and of its lead investigational peptide drug conjugate (PDC) candidate, sudocetaxel zendusortide (TH1902), in enabling targeted delivery of anticancer therapy.

Ascentage Pharma (6855.HK) today announced that the latest results from three preclinical studies of the company’s novel third-generation BCR-ABL inhibitor olverembatinib (HQP1351) and two key assets of Ascentage Pharma’s apoptosis-targeting pipeline, the Bcl-2 inhibitor lisaftoclax (APG-2575) and the MDM2-p53 inhibitor alrizomadlin (APG-115), have been selected for presentations at the 2023 American Association of Cancer Research Annual Meeting (AACR 2023).

PAVmed Inc. (NASDAQ: PAVM, PAVMZ) (“PAVmed” or the “Company”) today provided a business update for the Company and its subsidiaries, Lucid Diagnostics Inc. (NASDAQ: LUCD) (“Lucid”) and Veris Health Inc. (“Veris”), and presented financial results for the year ended December 31, 2022.

Tango Therapeutics, Inc. announced the acceptance of two oral and two poster presentations at the American Association for Cancer Research 2023 Annual Meeting, taking place from April 14-19, 2023 in Orlando, Florida.

Milestone Scientific Inc., a leading developer of computerized drug delivery instruments that provide painless and precise injections, announced that it has commenced sales of CompuFlo® Epidural disposables into the University Pain and Spine Center, which operates 7 offices across New Jersey and New York.

Curi Bio, a leading developer of human stem cell-based platforms for drug discovery, today announced the commercial launch of their MantaReady™ Skeletal Muscle Media optimized for human 3D engineered muscle tissue experiments.